Evidence map›Paper›PMID 41912754›Full record

ArticleInternational journal of hematology2026

Safety and efficacy of clofarabine for preconditioning intervention in patients undergoing allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphoblastic leukemia.

Akihiko Izumi, Takayoshi Tachibana, Takuya Miyazaki, Takaaki Takeda, Hiroaki Konishi, Maasa Abe, Takahiro Suzuki, Shuku Sato, Taisei Suzuki, Etsuko Yamazaki and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Akihiko IzumiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Takayoshi TachibanaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan. tachibana.tak.kt@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-7780-4459
Takuya MiyazakiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Takaaki TakedaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Hiroaki KonishiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Maasa AbeDepartment of Hematology, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.
Takahiro SuzukiDepartment of Hematology, Kitasato University School of Medicine, Sagamihara, Japan.
Shuku SatoDivision of Hematology, Shonan Kamakura General Hospital, Kamakura, Japan.
Taisei SuzukiDepartment of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
Etsuko YamazakiDepartment of Hematology, Yokohama Rosai Hospital, Yokohama, Japan.
Kana BandoDepartment of Hematology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan.
Yu UemuraDepartment of Hematology, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Hideaki NakajimaDepartment of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have suggested that intensive chemotherapy to induce bone marrow hypoplasia before allogeneic hematopoietic stem cell transplantation (HSCT) may improve outcomes in relapsed/refractory acute lymphoblastic leukemia. In this retrospective single-center study, we analyzed 14 patients who received clofarabine (CLO) as a preconditioning intervention (PCI) before HSCT between 2019 and 2024. PCI was defined as initiation of conditioning within 2 weeks after CLO. The median age was 34 years, and seven patients were not in remission at the time of CLO. CLO (30 mg/m

Indexed as

ClofarabineHematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningAdolescentAdultFemaleGraft vs Host DiseaseHumansMaleMiddle AgedRecurrenceRetrospective StudiesTransplantation, HomologousTreatment OutcomeYoung AdultClofarabineAcute lymphoblastic leukemiaAllogeneic hematopoietic cell transplantationClofarabinePreconditioning intervention

Identifiers

PMID41912754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.